Timosaponin A3 suppresses certain human tumor processes and has the potential to be developed as an anticancer agent. Reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. Induction of mitochondrial-dependent apoptosis in HepG2 human hepatocellular carcinoma cells.Timosaponin A3 is a potent inhibitor of U46619, that induces rat platelet aggregation and exhibited superior selectivity for the TP receptor vs. other G protein-coupled receptors and a PKC activator.
